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Alloreactive (allo)-HLAedirected T cell responses after HLA-mismatched allogeneic hematopoietic stem cell
transplantation and donor lymphocyte infusion are typically considered detrimental responses mediating
graft-versus-host disease (GVHD). Allo-HLA-reactive T cells with beneﬁcial and selective graft-versus-
leukemia (GVL) reactivity, however, can also be identiﬁed within an HLA-mismatched context. We investi-
gated whether allo-HLA class IIedirected T cells with beneﬁcial GVL reactivity induced in NOD/scid mice
engrafted with human chronic myelogenous leukemia in lymphoid blast crisis after treatment with donor
lymphocyte infusion e mediated detrimental xenogeneic GVHD as a result of broad off-target cross-reac-
tivity. The results demonstrate that beneﬁcial GVL reactivity and xenogeneic GVHD are mediated by separate
T cells. GVL reactivity was mediated by human T cells recognizing allo-HLA class II molecules, whereas
xenoreactivity was exerted by human T cells recognizing H-2 molecules. Taken together, our data indicate
a limited risk for detrimental off-target effects by allo-HLA class IIedirected T cells and thereby provide a basis
for the development of strategies for selecting allo-HLAerestricted T cells with selective GVL reactivity for
adoptive transfer after HLA-mismatched allogeneic hematopoietic stem cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION mediate severe GVHD. In contrast to HLA class I, constitutive
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a curative treatment for patients with hematologic
malignancies [1].However, thebeneﬁcial graft-versus-leukemia
(GVL) reaction after allo-HSCT is frequently accompanied by an
undesired detrimental complication, graft-versus-host disease
(GVHD). The incidence and severity of GVHD are reduced by
depletionofdonorTcells fromthe stemcell graft [2,3]; however,
donor T cell depletion also increases the risk for relapse of the
malignancy [2-4]. Although posttransplantation relapses can be
prevented or treated with donor lymphocyte infusion (DLI),
GVHD remains a signiﬁcant cause of morbidity and mortality
[5,6]. Therefore, therapies selectively stimulatingGVL responses
without GVHD are highly relevant to limit the toxicity and
broaden the use of allo-HSCT and DLI.
Because HLA-identical sibling donors are available for
only 30% of allo-HSCT recipients, the majority of allo-HSCTs
are performed with stem cell grafts from HLA-matched or
HLA-mismatched unrelated donors (URDs) [7,8]. Treatment
with HLA-mismatched allo-HSCT and DLI may result in
profound immune responses owing to high frequencies of
alloreactive donor T cells recognizing recipient - disparate
HLA molecules (allo-HLA) [9,10]. Due to constitutive HLA
class I expression on all nucleated cells, donor CD8þ T cells
recognizing mismatched HLA class I molecules are likely todgments on page 874.
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13.03.003expression of HLA class II molecules is conﬁned mainly to
normal and malignant hematopoietic cells [11-15], and high
HLA class II expression on nonhematopoietic cells is induced
only under inﬂammatory conditions [16-18]. Thus, under
noninﬂammatory circumstances, a disparity for HLA class II
molecules is anticipated to induce amore selective GVL effect
compared with HLA class I incompatibility. In support of this,
we have previously shown that clinically signiﬁcant GVL
effects can occur without GVHD after HLA class
IIemismatched DLI administered in the absence of clinically
evident inﬂammation [15,19], illustrating the potential
therapeutic beneﬁt of T cellebased immunotherapy across
HLA class II barriers for selective induction of GVL immunity.
Although allo-HLAedirected T cell immune responses
after HLA-mismatched allo-HSCT are typically considered
detrimental responses leading to graft rejection and GVHD,
we and others have previously demonstrated that beneﬁcial
speciﬁcities exist within the allo-HLAereactive T cell reper-
toire [20-24]. By analyzing the speciﬁcity of T cells at the time
of severe GVHD in a patient after HLA class Iemismatched
DLI, we demonstrated induction of an allo-HLA class
Iedirected immune response consisting of T cells with
detrimental as well as beneﬁcial reactivities [24]. Allo-HLA
class Iedirected CD8þ T cells with detrimental reactivities
recognized patient malignant cells as well as non-
hematopoietic cells, whereas CD8þ T cells with beneﬁcial
reactivities selectively recognized an overexpressed tumor-
associated antigen on the malignant cells of the patient [24].
Recently, in 2 patients who converted to donor hemato-
poiesis with concomitant severe GVHD after HLA classTransplantation.
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induction of allo-HLA class IIedirected CD4þ Tcells with both
detrimental and beneﬁcial reactivities [25]. Allo-HLA class
IIedirected CD4þ T cells with detrimental reactivities
recognized patient hematopoietic cells, as well as skin-
derived ﬁbroblasts cultured under inﬂammatory conditions
to induce HLA class II expression, but CD4þ T cells with
beneﬁcial reactivities selectively recognized patient hema-
topoietic cells [25]. These studies in individual patients
showed that allo-HLAereactive T cells with beneﬁcial and
detrimental reactivities are both retained within polyclonal
allo-HLAedirected immune responses after HLA-
mismatched allo-HSCT and DLI, providing a basis for
further development of strategies for selecting allo-
HLAereactive T cells speciﬁcally recognizing (malignant)
hematopoietic cells of the patient for adoptive transfer after
HLA-mismatched allo-HSCT.
The donor T cell repertoire has been shaped by selection
events in the thymus on the basis of tolerance for antigens in
HLA molecules that are shared between fully HLA-matched
patients and donors but not for antigens presented in allo-
HLA molecules [10,26]. Therefore, in the HLA-mismatched
setting, allo-HLAereactive immune responses may contain
T cells recognizing a variety of antigens presented in the
context of allo-HLA molecules [27,28], as well as T cells
recognizing multiple disparate HLA molecules [29]. This
broad cross-reactive recognition by allo-HLAereactive T cells
confers a risk for detrimental off-target reactivity in patients
and thus seriously hampers the clinical application of allo-
HLAerestricted T cells.
Development of a model that permits assessment of on-
target efﬁcacy as well as off-target toxicity of allo-
HLAedirected T cells in diverse HLA-mismatched situations
in vivo would be helpful in deﬁning potential risks and
beneﬁts of the application of allo-HLAerestricted T cells. We
previously used NOD/scid mice engrafted with human acute
lymphoblastic leukemia or chronic myelogenous leukemia in
lymphoid blast crisis to investigate the on-target efﬁcacy of
HLA class IIemismatched DLI [30,31]. Treatment of
leukemia-engrafted mice induced strong GVL effects medi-
ated by allo-HLA class IIerestricted CD4þ T cells. In those
studies, however, the beneﬁcial GVL effects after HLA class
IIemismatched DLI were accompanied by the development
of xenogeneic GVHD. Here, we investigated whether xeno-
reactivity in leukemia-engrafted NOD/scid mice treated with
HLA class IIemismatched DLI occurred as a result of broad
off-target cross-reactivity of allo-HLA class IIedirected
T cells. The results demonstrate that T cell responses
induced in vivo after HLA class IIemismatched DLI consisted
of leukemia-reactive T cells recognizing allo-HLA class II
molecules and xenoreactive T cells restricted by H-2 class I or
H-2 class II molecules, demonstrating that GVL reactivity and
xenogeneic GVHD are mediated by separate T cells with
distinct speciﬁcities. These data indicate the absence of
broad off-target toxicity by allo-HLA class IIedirected T cells
and thus provide a basis for the development of strategies for
selecting allo-HLAerestricted T cells with selective GVL
reactivity for adoptive transfer after HLA-mismatched allo-
HSCT.
MATERIALS AND METHODS
Patient and Donor Material
Bone marrow (BM) and peripheral blood (PB) samples were obtained
from a patient, and PB samples were obtained from a healthy URD after
approval by the Leiden University Medical Center’s Institutional Review
Board and provision of informed consent according to the Declaration ofHelsinki. Mononuclear cells were isolated by centrifugation over a Ficoll-
Hypaque gradient and cryopreserved. Leukemic cells were obtained from
a patient with chronic myelogenous leukemia in lymphoid blast crisis. The
patient and donor were fully matched for HLA-A, -B and -C alleles but
mismatched (underlined) for HLA-DR (patient: DRB1*1301, DRB1*1302,
DRB3*0101, DRB3*0301; donor: DRB1*0701, DRB1*1302, DRB3*0301,
DRB4*0101), HLA-DQ (patient: DQB1*0603, DQB1*0604; donor:
DQB1*0202, DQB1*0604), and HLA-DP (patient: DPB1*0301, DPB1*0401;
donor: DPB1*0201, DPB1*0501) alleles.
For DLI, CD3þ T cells were isolated from URD PB mononuclear cells
(PBMCs) by negative selection using a Pan T Isolation Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). The purity and composition of DLI were
analyzed by ﬂow cytometry after staining with FITC-labeled CD4 (BD
Biosciences, San Jose, CA), PE-labeled CD8 (Caltag; Invitrogen, Oslo,
Norway), and PECy5-labeled CD3 (BD Biosciences) monoclonal antibodies.
In Vivo NOD/scid Mouse Experiments
Female NOD/scid mice age 5 to 6 weeks were purchased from Charles
River Laboratories (Saint-Germain-sur-l’Abresle, France). All animal exper-
iments were conducted in accordance with institutional guidelines with
permission from the Leiden University Medical Center’s Animal Experi-
ments Committee. Mice were engrafted with primary human leukemic cells
from the patient and monitored as described previously [30]. In brief, after
i.v. injection of leukemic cells (10  106), engraftment of leukemia was
monitored weekly by ﬂow cytometry analysis of PB samples after staining
with FITC-labeled human CD19 (BD Biosciences) and PE-labeled mouse
CD45 (Ly5, Caltag) monoclonal antibodies. On detection of leukemic cells in
PB, mice were treated with DLI consisting of CD4þ (5  106 cells) and CD8þ
(3106 cells) Tcells by i.p. injection. After DLI, PB samples were analyzed for
the presence of leukemic cells and T cells by ﬂow cytometry after staining
with FITC-labeled human CD19 and CD4, PE-labeled human CD8, and
PECy5-labeled human CD3 monoclonal antibodies. During the experiments,
mice were monitored for the appearance of xenogeneic GVHD. Symptoms
including weight loss, anemia, hunched posture, rufﬂed fur, and reduced
mobility were used to diagnose xenogeneic GVHD.
Isolation of T Cell Clones
Mice were killed during GVL response and xenogeneic GVHD at day 45
post-DLI (80 days after leukemic inoculation), and T cell cloning was per-
formed from BM and spleen samples by single-cell sorting. In brief, organ
suspensions were stained with FITC-labeled human CD4 antibody and PE-
labeled human CD8 antibody, and CD4þ and CD8þ cells were sorted by
ﬂow cytometry into single cells per well in U-bottomed 96-well plates
containing irradiated (50 Gy) allogeneic PBMCs (0.05  106/well) as feeder
cells in 100 mL of Isocove’s modiﬁed Dulbecco’s medium (IMDM; Bio-
Whittaker, Verviers, Belgium) with 5% human serum, 5% FCS (BioWittaker),
IL-2 (120 IU/mL; Chiron, Amsterdam, The Netherlands), and phytohemag-
glutinin (0.8 mg/mL; Murex Biotec, Dartford, UK). Proliferating T cell clones
were selected and restimulated every 10 to 20 days.
Isolation of Stimulator Cells
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (EBV-
LCLs) from patient and donor were generated using standard procedures
and maintained in IMDM with 10% FCS. Donor EBV-LCLs were transduced
with retroviral vectors encoding the mismatched HLA class II alleles of the
patient, as described previously [30]. Dendritic cells (DCs) from NOD/scid
and C57BL/6mice were generated in vitro by culturing total BM from femora
in RPMI-1640medium (Invitrogen, Bleiswijk, The Netherlands) with 10% FCS
and 20 ng/mL recombinant murine granulocyte macrophage colony-
stimulating factor (Invitrogen) in 100-mm culture dishes. After 10 days,
BM-derived DCs were phenotypically analyzed by staining with PE-labeled
antibodies against mouse CD11c (clone HL3) and FITC-labeled antibodies
against mouse H-2Kd (clone SF1-1.1), H-2Db (clone 28-14-8), and I-Ag7
(clone OX-6) (all BD Biosciences). Single-cell suspensions of BM and spleen
cells for functional studies were obtained from euthanized healthy mice on
erythrocyte lysis. NOD/scid ﬁbroblasts were established from skin speci-
mens cultured in low-glucose DMEM (BioWhittaker) and 10% FCS with or
without recombinant human (rh) IFN-g (500 IU/mL) for 5 days. Phenotypical
analysis of BM and spleen cells and skin-derived ﬁbroblasts was performed
after staining with FITC-labeled monoclonal antibodies against mouse
H-2Kd, H-2Db, and I-Ag7.
Functional Studies
T cell clones (5000 cells/well) were coincubated with stimulator cells
(30,000 cells/well) in a ﬁnal volume of 150 mL of IMDM with 5% human
serum, 5% FCS, and 10 IU/mL IL-2 in 96-well U-bottomed plates. After
overnight incubation at 37C, release of IFN-g in 50 mL of culture superna-
tants wasmeasured by IFN-g ELISA (Sanquin, Amsterdam, The Netherlands).
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scid freshly isolated BM cells and in vitro cultured BM-derived DCs (30,000
cells/well) were preincubated with monoclonal antibodies against H-2Kd
(clone SF1-1.1; BD Biosciences), H-2Db (clone 28-14-8; BD Biosciences), or
anti-IAg7 (OX-6; Hybridoma Facility, Utrecht, The Netherlands) for 30
minutes at room temperature, followed by the addition of T cell clones
(5,000 cells/well).
The cytolytic activity of xenoreactive human T cell clones and murine
CD8þ T cell clone B12i [32,33] against NOD/scid BM-derived DCs and NOD/
scid ﬁbroblasts was determined using a 51Cr release cytotoxicity assay.
Target cells were labeled with Na251CrO4 (PerkinElmer, Groningen, The
Netherlands) for 1 hour at 37C and then incubated (2000 cells) with T cell
clones at a 10:1 effector:target ratio in 150 mL of culture medium. After 16
hours of incubation at 37C, 25 mL of supernatant was collected and
measured in a luminescence counter (TopCount NXT, PerkinElmer).
The cytokine release proﬁles of xenoreactive T cell clones (5000 cells/
well) after overnight stimulation with BM-derived DCs (30,000 cells/well)
and leukemia-reactive CD4þ T cell clones (5000 cells/well) on stimulation
with primary human leukemic cells (30,000 cells/well) was determined by
multi-Th1/Th2/Th17 cytokine ELISA (Qiagen, Venlo, The Netherlands).
IFN-g and TNF-a levels in plasma of treated and leukemia-engrafted
untreated mice were determined by IFN-g ELISA and TNF-a ELISA (Sanquin).
RESULTS
Isolation and Characterization of T Cells During GVL
Response and Xenogeneic GVHD
For analysis of the speciﬁcity of the T cell responses
during the GVL effect and xenogeneic GVHD, mice wereFigure 1. Isolation and characterization of T cell reactivity during GVL reactivity and
primary leukemic cells and then left untreated or given DLI at 35 days after leukemic
leukemic cells (–-–) and CD3þ T cells (–,–) in peripheral blood of mice were asse
hemoglobin (Hb) levels (mM) (–C–) in peripheral blood of mice were measured as w
mice (n ¼ 2). Mice were killed during the GVL effect and xenogeneic GVHD at day 4
starting time point of the GVL effect (Upper) and xenogeneic GVHD (Lower) in trea
patient- and donor-derived EBV-LCLs were tested for recognition by 91 CD4þ and 22 C
from 2 mice at day 45 post-DLI (80 days after leukemic inoculation). Each symbol re
culture supernatant in duplicate wells.,, T cell clones recognizing human leukemic
BM-derived DCs but not human leukemic cells; B, nonreactive T cell clones.engrafted with human leukemic cells and treated with DLI,
consisting of 59% CD4þ T cells and 35% CD8þ T cells. Patient
leukemic cells and donor lymphocytes were completely
matched for all HLA class I alleles and mismatched for HLA-
DRB1, -DRB3, -DQB1, and -DPB1 alleles, as described in
Materials and Methods. The expansion of human CD4þ and
CD8þ T cells correlated with the occurrence of GVL effects
and xenogeneic GVHD symptoms (Figure 1A). During GVL
reactivity and xenogeneic GVHD, human CD3þ T cells were
clonally isolated from BM and spleens of treated mice and
expanded. A total of 91 CD4þ and 22 CD8þ T cell clones were
obtained. All T cell clones were analyzed for reactivity against
patient leukemic cells and NOD/scid BM-derived DCs by IFN-
g ELISA (Figure 1B). The murine DCs expressed H-2 class I
and H-2 class II molecules (data not shown).
The reactivity of isolated CD4þ T cell clones could be
classiﬁed into groups based on the speciﬁc production of
IFN-g (>100 pg/mL) on stimulation with patient leukemic
cells (112-306 pg/mL IFN-g; n ¼ 15) or NOD/scid DCs (131-
363 pg/mL IFN-g; n ¼ 42). The majority of leukemia-reactive
CD4þ T cell clones were also shown to recognize patient-
derived, but not donor-derived, EBV-LCLs, indicating recog-
nition of alloantigens. In contrast to CD4þ T cell clones, none
of the isolated CD8þ T cell clones recognized patientxenogeneic GVHD after DLI. (A) NOD/scid mice were inoculated (day 0) with
inoculation (indicated by the arrow). (Upper) Absolute cell numbers of CD19þ
ssed by ﬂow cytometry. (Lower) Percentage of initial body weight (–B–) and
ell. Each symbol represents the mean values of untreated (n ¼ 2) and treated
5 post-DLI (80 days after leukemic inoculation). # indicates the approximate
ted mice. (B) Human primary leukemic cells, NOD/scid BM-derived DCs, and
D8þ T cell clones. The T cell clones were isolated from BM and spleens obtained
presents the mean release of IFN-g (pg/mL) by a single T cell clone in 50 mL of
cells but not NOD/scid BM-derived DCs;-, T cell clones recognizing NOD/scid
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whereas a number of CD8þ Tcell clones recognized NOD/scid
DCs (100-586 pg/mL; n ¼ 12). The remaining CD4þ (n ¼ 34)
and CD8þ (n ¼ 10) T cell clones were not reactive against any
of the tested target cells. TCR-Vb analysis demonstrated that
the T cell clones expressed various different TCR-Vb chains,
illustrating that the leukemia-reactive and xenoreactive
T cell responses were polyclonal (data not shown).
In conclusion, these data show induction of high
frequencies of human T cells with distinct speciﬁcities for
human leukemic cells and murine DCs, demonstrating that
GVL reactivity and xenogeneic GVHD in NOD/scid mice
treated with DLI are mediated by distinct T cells. The data
also show that the xenoreactive T cells were both CD4þ and
CD8þ, whereas all isolated leukemia-reactive T cells were
CD4þ, probably because of selective mismatching for HLA
class II alleles between donor and recipient.Identiﬁcation of MHC Restriction Elements of Isolated
T Cell Clones
To identify the HLA class II restriction molecules involved
in recognition of patient leukemic cells, leukemia-reactive
CD4þ T cell clones (n ¼ 10) were screened for recognition
of donor EBV-LCLs retrovirally transduced with patient
mismatched HLA-DR (B1*1301 or B3*0101), HLA-DQ
(B1*0603), and HLA-DP (B1*0301 or B1*0401) alleles using
IFN-g ELISA. CD4þ T cell clones were found to be directed
against mismatched HLA-DRB3*0101 (n ¼ 4), -DQB1*0603
(n ¼ 5), or -DPB1*0301 (n ¼ 1) (Figure 2).
Characterization of H-2 restriction alleles in recognition
of NOD/scid BM-derived DCs was performed with CD4þ (n ¼
5; clones A-E) and CD8þ (n¼ 5; clones F-J) xenoreactive Tcell
clones selected for expression of different TCR-Vb chains to
represent the diversity of the polyclonal xenoreactive T cell
response (data not shown). Flow cytometry analysis
demonstrated that NOD/scid DCs uniformly expressed H-2
class I and H-2 class II molecules (Figure 3A). Xenoreactive T
cell clones were incubated with NOD/scid BM-derived DCs
with and without blocking antibodies against H-2 class I (H-
2Kd and H-2Db) and H-2 class II (I-Ag7) alleles, and recogni-
tion was measured by IFN-g ELISA. Recognition of NOD/scid
DCs by xenoreactive CD4þ T cell clones could be blocked by
monoclonal antibody against H-2Kd for 1 T cell clone and by
antibody against I-Ag7 for 4 T cell clones (Figure 3B). For
xenoreactive CD8þ T cell clones, recognition of NOD/scid DCsFigure 2. Leukemia-reactive CD4þ T cell clones are restricted by HLA class II molecules
II molecules. Recognition of patient and donor EBV-LCLs retrovirally transduced with
representative leukemia-reactive CD4þ T cell clones is shown as the release of IFN-g (
clones tested, 4 clones were speciﬁc for HLA-DR, 5 clones were speciﬁc for HLA-DQ,could be blocked by monoclonal antibodies against H-2Kd
(n ¼ 3), H-2Db (n ¼ 1), or I-Ag7 (n ¼ 1) (Figure 3B).
To investigate whether the human CD8 and CD4 cor-
eceptors as expressed by the xenoreactive T cell clones
contributed to H-2erestricted recognition of murine DCs,
xenoreactive T cell clones were also incubated with NOD/scid
DCs with blocking antibodies against CD8 or CD4. Recogni-
tion of NOD/scid DCs by xenoreactive CD8þ and CD4þ T cell
clones was inhibited to varying degrees on blockage of the
coreceptors (Figure 3B). Some T cell clones displayed
a modest decrease in recognition, whereas others demon-
strated complete inhibition, indicating that human CD8 and
CD4 can serve as coreceptors for H-2 class Ie and H-2 class
IIerestricted recognition.
In conclusion, these data illustrate that T cells induced
during GVL reactivity and xenogeneic GVHD in NOD/scid
mice after HLA class IIemismatched DLI were restricted by
various disparate allo-HLA class II molecules and H-2 class I
or H-2 class II molecules, respectively. Furthermore, xeno-
reactive human T cells displayed H-2erestricted recognition
ofmurine cells that depended on the contribution of CD4 and
CD8 coreceptors to varying extents, illustrating genuine
characteristics of T cell allorecognition.Tissue Speciﬁcity and Reactivity of Xenoreactive T Cell
Clones
To determine the tissue speciﬁcity of xenoreactive T cell
clones, recognition of primary hematopoietic BM and spleen
cells from NOD/scid mice by xenoreactive CD4þ and CD8þ
T cell clones was measured by IFN-g ELISA. Flow cytometry
analysis showed that BM and spleen cells uniformly
expressed H-2 class I molecules and contained low
frequencies of H-2 class IIþ cells (Figure 4A). H-2 class Ie and
H-2 class IIerestricted xenoreactive T cell clones showed
variable production of IFN-g on incubation with primary
hematopoietic cells (Figure 4B). This recognitionwas speciﬁc,
as demonstrated by blocking with H-2especiﬁc monoclonal
antibodies (Figure 4C).
Alongwith hematopoietic cells, we tested the reactivity of
xenoreactive T cell clones against nonhematopoietic primary
NOD/scid skin-derived ﬁbroblasts using IFN-g ELISA. Because
xenoreactive T cell clones produced the proinﬂammatory
cytokine IFN-g on stimulation with murine cells, we tested
the reactivity of xenoreactive T cell clones against primary
NOD/scid skin-derived ﬁbroblasts cultured with and without. Leukemia-reactive CD4þ T cell clones are restricted by different allo-HLA class
HLA-DRB1*1301, -DRB3*0101, -DQB1*0603, -DPB1*0301, and -DPB1*0401 by
pg/mL) in 50 mL of culture supernatant. Of the 10 leukemia-reactive CD4þ T cell
and 1 clone was speciﬁc for HLA-DP.
Figure 3. Xenoreactive T cell clones are restricted by H-2 molecules. (A) H-2 class I (H-2Kd and H-2Db) and H-2 class II (I-Ag7) expression on NOD/scid
in vitroegenerated BM-derived DCs was measured by ﬂow cytometry. (B) Xenoreactive CD4þ and CD8þ T cell clones are restricted by different H-2 class I and H-2
class II molecules and are dependent on coreceptors for recognition. Recognition of NOD-scid BM-derived DCs by representative xenoreactive H-2 class Ierestricted
(Upper) and H-2 class IIerestricted (Lower) CD4þ and CD8þ T cell clones in the presence or absence of blocking antibodies was measured by IFN-g ELISA. The T cell
clones in brackets displayed similar recognition patterns as the representative T cell clone. Blocking was performed using monoclonal antibodies against H-2 class I
(H-2Kd and H-2Db), H-2 class II (I-Ag7), human CD8 (FK18), and human CD4 (RIV6). Of the 5 xenoreactive CD4þ T cell clones tested, 1 clone was H-2Kd erestricted (A),
and 4 clones were I-Ag7erestricted (B-E). Of the 5 xenoreactive CD8þ T cell clones tested, 3 clones were H-2Kderestricted (F-H), 1 clone was H-2Dberestricted (I), and
1 clone was I-Ag7erestricted (J). All T cell clones showed reduced IFN-g production on blocking of the coreceptor. The release of IFN-g (pg/mL) in 50 mL of culture
supernatant is shown.
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expression of H-2 class I molecules was up regulated after
treatment with rhIFN-g, whereas surface expression of H-2
class II remained absent [34-36] (Figure 5A). In line with H-2
surface expression, xenoreactive H-2 class Ierestricted T cell
clones recognized nontreated as well as cytokine-treated
skin ﬁbroblasts, whereas H-2 class IIerestricted T cell
clones showed no reactivity (Figure 5B).
Cytolytic Capacity and Cytokine Proﬁle of Xenoreactive
T Cell Clones
To determine whether xenoreactive human T cell clones
were capable of lysing murine cells, 51Cr-release cytotoxicity
assays were performed with all xenoreactive T cell clones for
which H-2 class I and H-2 class II restriction alleles were
identiﬁed. Murine CD8þ T cell clone B12i, which has been
showntoexert cytolyticactivityagainstmurineH-2bandH-2d
haplotypeeexpressing target cells, was included as a positive
control [32,33]. In contrast to murine CD8þ T cell clone B12i,
none of the xenoreactive T cell clones exhibited speciﬁc lysisagainst NOD/scid BM-derived DCs or primary skin-derived
ﬁbroblasts in 51Cr-release cytotoxicity assays (Figure 6A).
Because xenoreactive human T cells produced high levels
of IFN-g but showed no cytolytic capacity against murine
cells, the cytokine release proﬁles of xenoreactive CD4þ and
CD8þ T cell clones and leukemia-reactive CD4þ T cell clones
were analyzed and compared in more detail by multi-
cytokine ELISA. Xenoreactive T cells and leukemia-reactive
CD4þ T cell clones displayed similar cytokine proﬁles and
produced predominantly IFN-g, TNF-a, and IL-13 (Figure 6B).
Given that IFN-g and TNF-a have been implicated in the
development of xenogeneic GVHD, these cytokines were
measured in plasma of mice after treatment with DLI. Cyto-
kine levels in plasma of nontreated mice served as a control.
Levels of TNF-a were undetectable in plasma of both treated
and nontreated mice (data not shown). In contrast, high
levels of IFN-g were detected in treated mice at the time of
human T cell proliferation and development of GVL and
xenogeneic GVHD responses (Figure 6C), whereas IFN-g was
undetectable in the plasma of nontreated mice.
Figure 4. Xenoreactive human T cell clones recognize primary NOD/scid-derived hematopoietic cells. (A) H-2 class I (H-2Kd and H-2Db) and H-2 class II (I-Ag7)
expression on primary BM and spleen cells was measured by ﬂow cytometry. (B) NOD/scid BM (black bars, Upper) and spleen cells (black bars, Lower) were tested for
recognition by xenoreactive H-2 class IIerestricted CD4þ (B-E) and CD8þ (J) T cell clones and xenoreactive H-2 class Ierestricted CD4þ (A) and CD8þ (F-I) T cell clones
by IFN-g ELISA. The mean release of IFN-g(pg/mL) in 50 mL of culture supernatant in 4 independent experiments is shown. (C) Recognition of primary NOD/scid BM
cells by representative xenoreactive H-2 class Ierestricted (Upper) and H-2 class IIerestricted (Lower) CD4þ and CD8þ T cell clones in the presence or absence of
MHC-blocking antibodies as measured by IFN-g ELISA. The T cell clones in brackets displayed similar recognition patterns as the representative T cell clone. Blocking
was performed using monoclonal antibodies against H-2 class I (H-2Kd and H-2Db) or H-2 class II (I-Ag7). The release of IFN-g (pg/mL) in 50 mL of culture supernatants
is shown.
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CD8þ T cell clones produced high levels of IFN-g but failed to
mediate cytolysis. Furthermore, high levels of IFN-g were
detected in the plasma of mice at the time of xenogeneic
GVHD, suggesting that T cellemediated IFN-g release in vivo
plays a major causative role in the development of xeno-
geneic GVHD.
DISCUSSION
Using a NOD/scid mouse model for human acute
leukemia, we investigated the potential risk for broad
off-target toxicity by allo-HLA-reactive T cells induced after
HLA class IIemismatched DLI. Our results show that the
in vivoTcell response induced after HLA class IIemismatched
DLI consisted of human T cells exerting separate reactivitytoward human leukemic cells andmurine cells. GVL reactivity
was mediated by human T cells recognizing allo-HLA class II
molecules, whereas xenoreactivity was exerted by other
human T cells recognizing H-2 molecules. Thus, our
data show that allo-HLA class IIedirected T cells induce
beneﬁcial GVL effects without mediating broad off-target
toxicity.
Allogeneic T cell responses across HLA barriers are exerted
by T cells that have been educated to recognize self-
HLAeantigen complexes but are cross-reactive to allo-
HLAeantigen complexes [10,26]. Considering that allo-HLA
molecules are not encountered during thymic development,
and thus are not subjected to negative selection, allo-HLAe
reactive T cells may potentially exert cross-reactive recogni-
tion of multiple allo-HLAeantigen complexes [27-29]. In this
Figure 5. Xenoreactive H-2 class Ierestricted T cells recognize primary nonhematopoietic skin ﬁbroblasts. (A) Primary NOD/scid skin-derived ﬁbroblasts were
cultured with or without human IFN-g. After 5 days of cytokine treatment, H-2 class I and H-2 class II expression was measured by ﬂow cytometry using antibodies
against H-2Kd (   ), H-2Db (- - - - ), and I-Ag7 (d). The mean ﬂuorescence intensity (MFI) of stained and nonstained cells is shown. (B) Nontreated and cytokine-
treated primary skin-derived ﬁbroblasts were tested for recognition by xenoreactive T cell clones in IFN-g ELISA. Shown are the H-2 class IIerestricted CD8þ T cell
clone J, the H-2 class Ierestricted CD4þ T cell clone A, and H-2 class Ierestricted CD8þ T cell clones F, G, H, and I. The mean release of IFN-g (pg/mL) in 50 mL of culture
supernatant of single or duplicate wells is shown. nd, not determined.
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CD4þ T cells isolated during an in vivo allo-HLA class
IIedirected immune response did not exert broad allo-MHC
cross-reactivity. Restricted off-target toxicity toward speciﬁc
allo-HLA complexes by cross-reactive T cells with a deﬁned
speciﬁcity, as previously demonstrated for virus-speciﬁc
T cells [37], cannot be ruled out in our model, however. For
virus-speciﬁc T cells, this off-target toxicity was shown to be
restricted to speciﬁc mismatched HLA alleles for which no
thymic selection had occurred. For allo-HLA class IIedirected
CD4þ T cells, restricted off-target toxicity may be particu-
larly relevant for patients who have undergone trans-
plantation over multiple HLA class I and class II barriers, as
often occurs in haploidentical or cord blood allo-HSCT. Off-
target toxicity toward ubiquitous allo-HLA class I molecules
may potentially cause detrimental GVHD in these allo-HSCT
settings. Furthermore, in addition to restricted off-target
toxicity, on-target reactivity by allo-HLAereactive CD4þ
T cells might lead to detrimental GVHD owing to up-
regulation of HLA class II expression on nonhematopoietic
tissues during inﬂammatory circumstances. These inﬂam-
matory circumstances are likely to depend on complex
(combinations of) in vivo factors and thus cannot be accu-
rately investigatedorpredicted inourNOD/scidmousemodel.
We recently investigated the GVL effects of HLA-matched
(12/12 allele match) and HLA class IIemismatched DLI in
leukemia-engrafted NOD/scid mice [31] and demonstrated
impaired ability of HLA-matched DLI to mediate effective
GVL effects, in contrast to the profound and efﬁcient GVL
response seen after HLA class IIemismatched DLI. These
data strongly emphasize the relevance of HLA class
IIemismatched DLI as a treatment modality to combat
relapsed high-risk HLA class IIepositive acute leukemia. In
this study, we show that allo-HLA class IIedirected T cells
lack broad off-target reactivity, further supporting the use of
HLA class IIemismatched allo-HSCT and DLI to treat
aggressive leukemia. Our NOD/scid model provides a plat-
form for investigating GVL effects of speciﬁcminor andmajor
HLA disparities, as well as allo-HLAerestricted T cells with
selective GVL reactivity for adoptive transfer after HLA class
IIemismatched allo-HSCT.
Several in vivo models for xenogeneic GVHD developed in
immunodeﬁcient mice through the administration of humanPBMCs or puriﬁed T cells have been proposed as models for
human GVHD as well [38-42]. In these models, however,
whether xeno-reactivity as mediated by human T cells
sufﬁciently resembles HLA-restricted alloreactivity in
humans remains unknown. In this study, we found that
xenoreactive human CD4þ and CD8þ T cells were restricted
by H-2 class I and H-2 class II molecules. H-2 class
Ierestricted CD4þ and H-2 class IIerestricted CD8þ T cell
clones were also isolated, and H-2erestricted recognition of
murine target cells by xenoreactive CD4þ and CD8þ T cell
clones was shown to depend to a varying extent on co-
receptor interaction with H-2 molecules. These ﬁndings
demonstrate the genuine characteristics of the alloreactive
T cell repertoire, similar to that observed for allo-
HLAerestricted T cell reactivity in humans. The xenor-
eactive human CD8þ and CD4þ T cells produced signiﬁcant
levels of IFN-g but failed to exert direct cytolytic activity
against murine target cells. This lack of cytolytic activity
might be explained by a species barrier in accessory mole-
cules required for adequate T cell activation and lysis of
target cells. Considering that we and others have demon-
strated that CD8 and CD4 coreceptors contributed to the
avidity of the interaction between human T cell and murine
cells [43-46], a species barrier between other accessory
molecules is the more likely explanation of the lack of lytic
effector function of xenoreactive T cells. This idea is sup-
ported by studies showing that the introduction of human
CD54 and/or CD58molecules intomurine cells is required for
human T cellemediated cytotoxicity [47,48] and is in line
with our observations [49] that CD54 expression on human
cells is also essential for high-avidity interaction with allo-
reactive T cells. Thus, our in vitro ﬁndings suggest that the
effector phase of xenogeneic GVHD in vivo is likely mediated
by the release of soluble factors by xenoreactive T cells rather
than by direct cytotoxicity. Previous mouse studies with
murine T cells have shown that inﬂammatory soluble factors
play an essential role in GVHD by mediating bone marrow
suppression [50] and inducing characteristic cutaneous and
intestinal lesions [51], as illustrated by the absence of these
detrimental effects in the presence of neutralizing antibodies
against IFN-g and TNF-a [50,51]. In addition, rapid-onset
lethal anemia, a characteristic feature of xenogeneic GVHD,
can result from sustained systemic exposure to IFN-g, as was
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Figure 6. Cytolytic capacity and cytokine proﬁle of xenoreactive T cell clones.
(A) The cytolytic capacity of xenoreactive H-2 class Ie and H-II class
IIerestricted CD4þ and CD8þ T cell clones was measured against NOD-scid
BM-derived DC (black bars) and skin-derived ﬁbroblasts (white bars) in
a 16-hour 51Cr-release cytotoxicity assay (effector:target ratio of 10:1). A
murine CD8þ T cell clone (B12i) served as positive control. (B) Cytokine release
in 3 xenoreactive T cell clones (B, F, and J) after stimulation with NOD/scid BM-
derived DCs and in 3 leukemia-reactive CD4þ T cell clones on stimulation with
primary human leukemic cells was measured by multicytokine ELISA. The
different T cell clones are represented by clear, gray, and black bars. The release
of cytokines (ng/mL) in 50 mL of supernatant is shown. (C) Levels of IFN-g and
TNF-a in plasma of treated (n ¼ 2) and untreated (n ¼ 2) leukemia-engrafted
mice were determined by ELISA. Levels of TNF-a were undetectable in treated
and untreated mice (data not shown). Average  SD IFN-g levels (pg/mL) in
10 mL of plasma from treated mice (A) and untreated (A) leukemia-engrafted
mice. The solid line indicated the rapid expansion of T cells in treated mice
after DLI.
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[52]. In the present study, we found pathological levels of
IFN-g in mice treated with DLI at the time of anemia, further
supporting the idea that a cytokine storm, rather than direct
cytolysis, is induced by xenoreactive human T cells, and that
this cytokine storm is the main cause of xenogeneic GVHD in
immunodeﬁcient mice after DLI.
It has been suggested that noneMHC-restricted effector
natural killer T cells play a role in antitumor immunity [53]
and xenogeneic GVHD [54] in immunodeﬁcient mice. For
all CD4þ and CD8þ T cell clones analyzed in the present
study, however, recognition of human and murine targetcells could be blocked by anti-MHCespeciﬁc monoclonal
antibodies, and MHC restriction molecules could be identi-
ﬁed. Thus, our data indicate a dominant role for conventional
MHC-restricted T cells in GVL effects and xenogeneic GVHD
induced in leukemia-engrafted NOD/scid mice after treat-
ment with human DLI.
In conclusion, in this study, we have shown that allo-HLA
class IIedirected T cells induced in vivo in leukemia-
engrafted NOD/scid mice after HLA class IIemismatched
DLI displayed on-target GVL reactivity without broad off-
target toxicity. Our results provide a basis for the develop-
ment of strategies for selecting allo-HLAerestricted T cells
with selective GVL reactivity for adoptive transfer after HLA-
mismatched allo-HSCT.
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